Standard chemo preferable to MDRs for Hodgkin's disease

Gespeichert in:

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2006

Schlagwörter:	Doxorubicin Etoposide Bleomycin Vinblastine Objective Response Rate

Anmerkung:	© Adis International Ltd 2006

Übergeordnetes Werk:	Enthalten in: Inpharma weekly - Auckland : ADIS internat., 1975, 1521(2006), 1 vom: Jan., Seite 15-15
Übergeordnetes Werk:	volume:1521 ; year:2006 ; number:1 ; month:01 ; pages:15-15

Links:	Volltext

DOI / URN:	10.2165/00128413-200615210-00033

Katalog-ID:	SPR035239549

Internformat


LEADER	01000caa a22002652 4500
001	SPR035239549
003	DE-627
005	20230520013128.0
007	cr uuu---uuuuu
008	201007s2006 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.2165/00128413-200615210-00033 \|2 doi
035			\|a (DE-627)SPR035239549
035			\|a (SPR)00128413-200615210-00033-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Standard chemo preferable to MDRs for Hodgkin's disease
264		1	\|c 2006
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Adis International Ltd 2006
650		4	\|a Doxorubicin \|7 (dpeaa)DE-He213
650		4	\|a Etoposide \|7 (dpeaa)DE-He213
650		4	\|a Bleomycin \|7 (dpeaa)DE-He213
650		4	\|a Vinblastine \|7 (dpeaa)DE-He213
650		4	\|a Objective Response Rate \|7 (dpeaa)DE-He213
773	0	8	\|i Enthalten in \|t Inpharma weekly \|d Auckland : ADIS internat., 1975 \|g 1521(2006), 1 vom: Jan., Seite 15-15 \|w (DE-627)373977859 \|w (DE-600)2127607-9 \|x 2230-6056 \|7 nnns
773	1	8	\|g volume:1521 \|g year:2006 \|g number:1 \|g month:01 \|g pages:15-15
856	4	0	\|u https://dx.doi.org/10.2165/00128413-200615210-00033 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_SPRINGER
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_20
912			\|a GBV_ILN_206
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_4305
951			\|a AR
952			\|d 1521 \|j 2006 \|e 1 \|c 01 \|h 15-15

Indexfelder

matchkey_str	article:22306056:2006----::tnadhmpeealtmrfr
hierarchy_sort_str	2006
publishDate	2006
allfields	10.2165/00128413-200615210-00033 doi (DE-627)SPR035239549 (SPR)00128413-200615210-00033-e DE-627 ger DE-627 rakwb eng Standard chemo preferable to MDRs for Hodgkin's disease 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2006 Doxorubicin (dpeaa)DE-He213 Etoposide (dpeaa)DE-He213 Bleomycin (dpeaa)DE-He213 Vinblastine (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1521(2006), 1 vom: Jan., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1521 year:2006 number:1 month:01 pages:15-15 https://dx.doi.org/10.2165/00128413-200615210-00033 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1521 2006 1 01 15-15
spelling	10.2165/00128413-200615210-00033 doi (DE-627)SPR035239549 (SPR)00128413-200615210-00033-e DE-627 ger DE-627 rakwb eng Standard chemo preferable to MDRs for Hodgkin's disease 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2006 Doxorubicin (dpeaa)DE-He213 Etoposide (dpeaa)DE-He213 Bleomycin (dpeaa)DE-He213 Vinblastine (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1521(2006), 1 vom: Jan., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1521 year:2006 number:1 month:01 pages:15-15 https://dx.doi.org/10.2165/00128413-200615210-00033 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1521 2006 1 01 15-15
allfields_unstemmed	10.2165/00128413-200615210-00033 doi (DE-627)SPR035239549 (SPR)00128413-200615210-00033-e DE-627 ger DE-627 rakwb eng Standard chemo preferable to MDRs for Hodgkin's disease 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2006 Doxorubicin (dpeaa)DE-He213 Etoposide (dpeaa)DE-He213 Bleomycin (dpeaa)DE-He213 Vinblastine (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1521(2006), 1 vom: Jan., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1521 year:2006 number:1 month:01 pages:15-15 https://dx.doi.org/10.2165/00128413-200615210-00033 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1521 2006 1 01 15-15
allfieldsGer	10.2165/00128413-200615210-00033 doi (DE-627)SPR035239549 (SPR)00128413-200615210-00033-e DE-627 ger DE-627 rakwb eng Standard chemo preferable to MDRs for Hodgkin's disease 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2006 Doxorubicin (dpeaa)DE-He213 Etoposide (dpeaa)DE-He213 Bleomycin (dpeaa)DE-He213 Vinblastine (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1521(2006), 1 vom: Jan., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1521 year:2006 number:1 month:01 pages:15-15 https://dx.doi.org/10.2165/00128413-200615210-00033 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1521 2006 1 01 15-15
allfieldsSound	10.2165/00128413-200615210-00033 doi (DE-627)SPR035239549 (SPR)00128413-200615210-00033-e DE-627 ger DE-627 rakwb eng Standard chemo preferable to MDRs for Hodgkin's disease 2006 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier © Adis International Ltd 2006 Doxorubicin (dpeaa)DE-He213 Etoposide (dpeaa)DE-He213 Bleomycin (dpeaa)DE-He213 Vinblastine (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213 Enthalten in Inpharma weekly Auckland : ADIS internat., 1975 1521(2006), 1 vom: Jan., Seite 15-15 (DE-627)373977859 (DE-600)2127607-9 2230-6056 nnns volume:1521 year:2006 number:1 month:01 pages:15-15 https://dx.doi.org/10.2165/00128413-200615210-00033 lizenzpflichtig Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305 AR 1521 2006 1 01 15-15
language	English
source	Enthalten in Inpharma weekly 1521(2006), 1 vom: Jan., Seite 15-15 volume:1521 year:2006 number:1 month:01 pages:15-15
sourceStr	Enthalten in Inpharma weekly 1521(2006), 1 vom: Jan., Seite 15-15 volume:1521 year:2006 number:1 month:01 pages:15-15
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	Doxorubicin Etoposide Bleomycin Vinblastine Objective Response Rate
isfreeaccess_bool	false
container_title	Inpharma weekly
publishDateDaySort_date	2006-01-01T00:00:00Z
hierarchy_top_id	373977859
id	SPR035239549
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035239549</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230520013128.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2006 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200615210-00033</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035239549</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200615210-00033-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Standard chemo preferable to MDRs for Hodgkin's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2006</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2006</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxorubicin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Etoposide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bleomycin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vinblastine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1521(2006), 1 vom: Jan., Seite 15-15</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1521</subfield><subfield code="g">year:2006</subfield><subfield code="g">number:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:15-15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200615210-00033</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1521</subfield><subfield code="j">2006</subfield><subfield code="e">1</subfield><subfield code="c">01</subfield><subfield code="h">15-15</subfield></datafield></record></collection>
ppnlink_with_tag_str_mv	@@773@@(DE-627)373977859
format	electronic Article
delete_txt_mv	keep
collection	springer
remote_str	true
illustrated	Not Illustrated
issn	2230-6056
topic_title	Standard chemo preferable to MDRs for Hodgkin's disease Doxorubicin (dpeaa)DE-He213 Etoposide (dpeaa)DE-He213 Bleomycin (dpeaa)DE-He213 Vinblastine (dpeaa)DE-He213 Objective Response Rate (dpeaa)DE-He213
topic	misc Doxorubicin misc Etoposide misc Bleomycin misc Vinblastine misc Objective Response Rate
spellingShingle	misc Doxorubicin misc Etoposide misc Bleomycin misc Vinblastine misc Objective Response Rate Standard chemo preferable to MDRs for Hodgkin's disease
topic_unstemmed	misc Doxorubicin misc Etoposide misc Bleomycin misc Vinblastine misc Objective Response Rate
topic_browse	misc Doxorubicin misc Etoposide misc Bleomycin misc Vinblastine misc Objective Response Rate
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	Inpharma weekly
hierarchy_parent_id	373977859
hierarchy_top_title	Inpharma weekly
isfreeaccess_txt	false
familylinks_str_mv	(DE-627)373977859 (DE-600)2127607-9
title	Standard chemo preferable to MDRs for Hodgkin's disease
ctrlnum	(DE-627)SPR035239549 (SPR)00128413-200615210-00033-e
title_full	Standard chemo preferable to MDRs for Hodgkin's disease
journal	Inpharma weekly
journalStr	Inpharma weekly
lang_code	eng
isOA_bool	false
recordtype	marc
publishDateSort	2006
contenttype_str_mv	txt
container_start_page	15
container_volume	1521
format_se	Elektronische Aufsätze
doi_str_mv	10.2165/00128413-200615210-00033
title_sort	standard chemo preferable to mdrs for hodgkin's disease
title_auth	Standard chemo preferable to MDRs for Hodgkin's disease
abstract	© Adis International Ltd 2006
abstractGer	© Adis International Ltd 2006
abstract_unstemmed	© Adis International Ltd 2006
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER SSG-OLC-PHA GBV_ILN_20 GBV_ILN_206 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4305
container_issue	1
title_short	Standard chemo preferable to MDRs for Hodgkin's disease
url	https://dx.doi.org/10.2165/00128413-200615210-00033
remote_bool	true
ppnlink	373977859
mediatype_str_mv	c
isOA_txt	false
hochschulschrift_bool	false
doi_str	10.2165/00128413-200615210-00033
up_date	2024-07-03T13:57:02.287Z
_version_	1803566472025341952
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">SPR035239549</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230520013128.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">201007s2006 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.2165/00128413-200615210-00033</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR035239549</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)00128413-200615210-00033-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Standard chemo preferable to MDRs for Hodgkin's disease</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2006</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">© Adis International Ltd 2006</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Doxorubicin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Etoposide</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Bleomycin</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vinblastine</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Objective Response Rate</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Inpharma weekly</subfield><subfield code="d">Auckland : ADIS internat., 1975</subfield><subfield code="g">1521(2006), 1 vom: Jan., Seite 15-15</subfield><subfield code="w">(DE-627)373977859</subfield><subfield code="w">(DE-600)2127607-9</subfield><subfield code="x">2230-6056</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:1521</subfield><subfield code="g">year:2006</subfield><subfield code="g">number:1</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:15-15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.2165/00128413-200615210-00033</subfield><subfield code="z">lizenzpflichtig</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">1521</subfield><subfield code="j">2006</subfield><subfield code="e">1</subfield><subfield code="c">01</subfield><subfield code="h">15-15</subfield></datafield></record></collection>
score	7.399617

Nicht das Richtige dabei?

Schreiben Sie uns!

Standard chemo preferable to MDRs for Hodgkin's disease

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?